文献速递眼底病与葡萄膜炎

全视网膜光凝与阿柏西普治疗增殖性糖尿病视网膜病变的机制评估:CLARITY子研究

Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

结果显示阿柏西普组新生血管消退更早且更完全,但两组在52周时视网膜动静脉血氧饱和度差值和无灌注区面积变化上无显著差异。

要点

  • 阿柏西普组新生血管面积在12周时完全消退,PRP组部分消退(P=0.019)。
  • 52周时两组视网膜动静脉血氧饱和度差值变化无显著差异(P=0.10)。
  • 52周时两组视网膜无灌注区面积变化无显著差异(P=0.46)。

核心结论

  • 玻璃体腔注射阿柏西普相比PRP能更早且更完全地消退增殖性糖尿病视网膜病变的新生血管。
  • 两组在52周时视网膜血管内血氧饱和度整体变化和视网膜无灌注区面积上无显著差异。

研究设计与样本

  • 基线及第52周进行视网膜血氧测定和超广角血管造影,基线、第12周和第52周进行超广角彩色眼底成像。

主要发现

  • PRP组视网膜动静脉血氧饱和度差值从基线36.7%增至39.7%,阿柏西普组从33.4%降至32.5%,第52周组间差异为4.0%(95%CI -0.08至8.8;P=0.10)。
  • PRP组和阿柏西普组基线平均视网膜无灌注区面积分别为125.1 DA和131.2 DA,第52周分别增至156.1 DA和158.4 DA(P=0.46)。
  • PRP组新生血管中位面积从基线0.98 DA降至第12周0.68 DA,阿柏西普组从0.70 DA降至0 DA(P=0.019);第52周分别为0.24 DA和0 DA(P=0.45)。

临床怎么用

  • 对于增殖性糖尿病视网膜病变,阿柏西普可考虑作为促进新生血管更快更完全消退的治疗选择。
  • 治疗52周内,PRP与阿柏西普对全球视网膜血氧饱和度和无灌注区面积的影响无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to study the effects of panretinal photocoagulation (PRP) and intravitreal aflibercept on retinal vessel oxygen saturations, area of retinal nonperfusion, and area of neovascularization in proliferative diabetic retinopathy. METHODS: This is a prospective randomized single center study. Forty patients with proliferative diabetic retinopathy were randomized to PRP or intravitreal aflibercept treatment for 52 weeks. Retinal oximetry and ultra-widefield angiography were performed at baseline and week 52. Ultra-widefield color fundus imaging was performed at baseline, week 12, and week 52. The outcomes were retinal arterio-venous oximetry differences (AVD), area of retinal nonperfusion, and area of neovascularization in disc areas (DA). RESULTS: The AVD in the PRP group increased from 36.7% at baseline to 39.7%, whereas it decreased from 33.4% to 32.5% in the aflibercept group. The difference in AVD between groups at week 52 was 4.0% (95% confidence interval, -0.08, 8.8; P = 0.10). The baseline mean area of retinal nonperfusion of 125.1 DA and 131.2 DA in the PRP and aflibercept groups increased to 156.1 DA and 158.4 DA, respectively, at week 52 (P = 0.46). The median baseline area of neovascularization decreased from 0.98 DA to 0.68 DA in the PRP group and from 0.70 DA to 0 DA in the aflibercept group at week 12 (P = 0.019). At week 52, this measured 0.24 DA in the PRP group and 0 DA in the aflibercept group (P = 0.45). CONCLUSIONS: Intravitreal aflibercept achieved an earlier and complete regression of neovascularization in proliferative diabetic retinopathy compared with PRP. There were no significant differences in global change in intravascular oxygen saturation or areas of retinal nonperfusion between the two groups by 52 weeks.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Nicholson L, Crosby-Nwaobi R, Vasconcelos JC, et al. Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy. Invest Ophthalmol Vis Sci. 2018. PMID: 30372756. doi:10.1167/iovs.17-23509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。